Cerebrolysin: The Neurotrophic Peptide Complex for Brain Health

Cerebrolysin is a mixture of small peptides and amino acids derived from purified pig brain protein that appears to mimic some actions of the brain's own growth factors. It is approved in about 50 countries for conditions such as stroke and dementia, but it is not FDA-approved in the United States, and human trials show mixed results — modest benefits on some recovery measures and no clear effect on others. It is a genuinely interesting compound, and also a good example of why careful reading of evidence matters.

What Is Cerebrolysin?

Unlike most peptides discussed on this site, Cerebrolysin is not a single molecule. It is a standardized preparation made by breaking down purified porcine brain proteins with enzymes. The result is a solution of low-molecular-weight peptides plus free amino acids. It has been manufactured in Europe for decades and is given by intramuscular injection or intravenous infusion, typically in courses supervised by neurologists in the countries where it is approved.

Because it is a mixture, it does not act on one receptor. Laboratory studies suggest it behaves in some ways like neurotrophic factors — the brain's natural proteins, such as BDNF and NGF, that support neuron survival and the formation of new connections.

How Brain Aging and Injury Unfold

To understand why researchers are interested in Cerebrolysin, it helps to look at three overlapping processes that contribute to neurodegeneration and poor recovery after injury:

1. Neuroinflammation. The brain's resident immune cells, microglia, can shift from a protective, clean-up role into a chronically inflammatory state that releases cytokines such as IL-6 and TNF-alpha.
2. Impaired energy metabolism. The brain uses roughly a fifth of the body's energy. Insulin resistance and mitochondrial dysfunction can reduce how well neurons use glucose, and some researchers have proposed describing Alzheimer's disease as a form of "brain insulin resistance."
3. Energy failure and cell loss. When inflammation and poor fuel supply persist, neurons struggle to maintain themselves and can die through programmed cell death.

This is a useful framework rather than a complete explanation. Genetics, vascular health, sleep and protein aggregation (such as amyloid and tau) also play major roles. The point is that brain decline is a physiological process with identifiable drivers — several of which, such as blood pressure, blood sugar, sleep and physical activity, are well within the reach of standard medicine. I explore the energy side further in The Role of Mitochondrial Health in Aging.

Proposed Mechanisms of Cerebrolysin

In cell and animal studies, Cerebrolysin has been reported to:

• Support neuron survival and reduce programmed cell death after injury
• Promote formation of new synapses (synaptogenesis) and, in some models, new neurons
• Encourage new blood vessel growth around injured tissue
• Reduce markers of neuroinflammation and, in Alzheimer's models, amyloid-related changes

These findings are biologically plausible, but they come largely from animals. Effects seen in a mouse brain after a controlled injury do not automatically translate to people with complex, long-developing disease.

What Human Trials of Cerebrolysin Show

Cerebrolysin has more human data than most compounds discussed in peptide circles, which is to its credit. The picture is mixed:

• Stroke recovery. The CARS trial, a randomized, placebo-controlled study published in 2016, found better upper-limb motor recovery at 90 days when Cerebrolysin was added to standard rehabilitation. The authors described it as exploratory and called for larger trials.
• Acute stroke overall. A 2023 Cochrane review pooling randomized trials found no clear effect on death, and a possible increase in non-fatal serious adverse events, with evidence certainty ranging from moderate to very low. Some major trials were supported by the manufacturer.
• Dementia. Trials in vascular and Alzheimer's-type dementia have reported improvements on some cognitive and global scales, but studies are generally small, short and heterogeneous, and they have not led to approval in the United States or recommendation in most U.S. guidelines.
• Traumatic brain injury and other uses. Data are emerging but limited.

Earlier online material sometimes cites dramatic results, such as patients stopping Parkinson's medication entirely or reversal of brain atrophy. I have not found reliable trial evidence supporting those claims, and I do not repeat them.

Why Isn't Cerebrolysin Available in the U.S.?

It is tempting to assume that useful treatments are kept from patients for business reasons. The more accurate explanation is ordinary: FDA approval requires a sponsor to submit an application supported by adequate, well-controlled trials, and the existing evidence for Cerebrolysin is mixed and has not been taken through that process here. Because it is derived from animal tissue, consistency, purity and allergy risk are also legitimate concerns.

As of this writing, Cerebrolysin is not FDA-approved and is not legally marketed in the United States. Importing unapproved drugs for personal use carries legal and quality risks, and products sold online cannot be verified. Check current FDA guidance, as rules can change.

Safety Considerations

Reported side effects in trials include dizziness, headache, agitation, sweating and injection-site reactions. Because it is derived from porcine protein, allergic reactions — including rare serious ones — are possible. People with severe kidney disease, seizure disorders, pregnancy or known pork-protein allergy require particular caution, and interactions with antidepressants have been raised as a theoretical concern.

A Practical Brain Health Plan

If you are worried about memory or cognitive decline, the first steps are evaluation and proven risk reduction: assessing blood pressure, blood sugar, lipids, thyroid function, B12, sleep apnea, hearing, mood and medications that can affect cognition. Regular exercise, good sleep and treating vascular risk factors have the strongest evidence for protecting the brain. Compounds such as Semax or Dihexa are sometimes discussed online, but their human data are thinner still; you can read about them in Selank and Semax: Russia's Cognitive Peptides Examined.

At Laeeq M.D., I begin any cognitive concern with a thorough internal medicine workup and refer to neurology when appropriate. Any discussion of investigational compounds comes after that, with honest attention to regulatory status and evidence.

Sources

• Cerebrolysin and Recovery After Stroke (CARS): A Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial — Muresanu DF, et al. Stroke, 2016
• Cerebrolysin for acute ischaemic stroke — Ziganshina LE, et al. Cochrane Database of Systematic Reviews, 2023

Book a Consultation

If you or a family member are concerned about memory, focus or recovery after a neurological event, a careful medical evaluation is the right starting point. Dr. Laeeq offers 60-minute consultations, virtually or in person in Reston, VA. Book a consultation to review your history, labs and options.

This article is for educational purposes and is not medical advice. Discuss any treatment with a licensed physician who knows your history.